Philip Morris Stock Surges After FDA’s ZYN Signal — What Investors Think Comes Next
Philip Morris shares climbed 6.5% to $182.11 on Monday after the U.S. FDA said it would not prioritize enforcement against some nicotine pouches and e-cigarettes still under review. The guidance boosted investor hopes for ZYN Ultra’s U.S. launch, following a 23.5% drop in ZYN shipments last quarter. FDA clarified the policy is not a full approval and could change.